Anmelden Kostenlos registrieren

Cue Biopharma Inc Verschuldung / Eigenkapital

Was ist das Verschuldung / Eigenkapital von Cue Biopharma Inc?

Verschuldung / Eigenkapital von Cue Biopharma Inc ist 0.66

Was ist die Definition von Verschuldung / Eigenkapital?



Die Verschuldung zu Eigenkapital ist ein Finanzverhältnis, das den relativen Anteil des Eigenkapitals und der Verschuldung angibt, die zur Finanzierung der Vermögenswerte eines Unternehmens verwendet werden.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Verschuldung / Eigenkapital von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Cue Biopharma Inc

Was macht Cue Biopharma Inc?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Unternehmen mit verschuldung / eigenkapital ähnlich Cue Biopharma Inc